Compass Therapeutics Inc

Insider buys spark a brief rally for Compass Therapeutics, showing leadership confidence amid weak pricing and uncertain clinical prospects.

Insider buying at Compass Therapeutics shows executives see value amid a 68% share drop—an opportunity for investors to gauge upcoming oncology milestones and proxy outcomes.

Compass Therapeutics insider buy: CFO Neil Lerner’s 15K‑share purchase at $1.89 signals confidence amid a 52‑week low, highlighting strong antibody pipeline and upcoming regulatory milestones.